anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed herein are bone marrow stromal cells. The bone marrow stromal cells may express and/or secrete TGF-β1. The bone marrow stromal cells may express CXCR4. Also disclosed herein is a method of treating pain in a subject in need thereof. The method of treating may include administration of the bone marrow stromal cells to the subject. The pain may be neuropathic pain.
Tolcapone is a brain penetrant catechol-O-methyltransferase (COMT) inhibitor. It will be administered in a single 200mg dosage once in randomized, double-blind, counterbalanced fashion with a placebo.
The use of betaine type zwitterionic surfactant to stabilize peroxide source belongs to the field of chemistry. The peroxide source is carbamide peroxide, calcium peroxide, percarbonate, perborate, hydrogen peroxide or polyvinylpyrrolidone hydrogen peroxide complex. The betaine zwitterionic surfactant may be cocamidopropyl dimethylamine caprolactone. Can be used to stabilize peroxide sources in water, methanol, ethanol, propylene glycol, glycerol, sorbitol, propylene glycol, polyacrylic acid. Can be used for water-containing or water-free liquid, paste and colloid. Can be used for preparing toothpaste containing peroxide source and added with sweetener, essence, thickener, filler, and humectant. The invention uses the betaine type zwitterionic surfactant in the preparation of industrial products such as disinfection products, daily chemical products, medical products and the like containing peroxide sources, is particularly suitable for preparing toothpaste, mouthwash and disinfectors containing the peroxide sources, and has very positive significance.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to urology, and can be used for treating relative sterility in varicocele. That is ensured by preoperative testicle Doppler sonography (size and volume), evaluation of spermogram and hormonal status (blood plasma testosterone concentration). It is followed by calculation of a testicle atrophy index (TAI), and if the testicle atrophy index exceeds 22 % in normal testosteronemia, and if the testicle atrophy index exceeds 15% in hypertestosteronemia, the Mannar subinguinal microsurgical varicocelectomy is required. The patients not showing any improvements of the spermogram values within 12 months after varicocelectomy are additionally prescribed with a hormone-stimulating therapy by human chorionic gonadotropin preparations. ^ EFFECT: method allows higher clinical effectiveness and lower drug-induced body burden due to an adequate choice of a therapeutic approach consisting in proved prescription of the hormone-stimulating therapy. ^ 5 ex
When treating diseases, clinicians traditionally aim for pain reduction and functional recovery. This is also true for chronic musculoskeletal diseases. However, the psychosocial support required to improve the general health perception of patients is becoming increasingly important. In clinical practice, it is essential to evaluate the quality of life and general well-being and to evaluate the patient completely biopsychosocially . Determining the factors affecting the quality of life is important in terms of contributing to the rehabilitation processes and treatment plans of CMP patients. In this direction, our study aims to examine the factors affecting the quality of life.

When treating diseases, clinicians traditionally aim for pain reduction and functional recovery. This is also true for chronic musculoskeletal diseases. However, the psychosocial support required to improve the general health perception of patients is becoming increasingly important. In clinical practice, it is essential to evaluate the quality of life and general well-being and to evaluate the patient completely biopsychosocially . Determining the factors affecting the quality of life is important in terms of contributing to the rehabilitation processes and treatment plans of CMP patients. In this direction, our study aims to examine the factors affecting the quality of life.
A sunscreen is disclosed that promotes ocean health, especially for coral reefs. The sunscreen includes an active sunscreen component, a delivery component, and one or more alkalinity enhancing components. The sunscreen component filters or blocks some amount of harmful solar radiation from affecting the wearer's skin and is preferably reef-safe and free from ingredients that pose health risks to wearers. The alkalinity enhancing components counteracts ocean acidification, or raises the pH, of the local environment, e.g., in the vicinity of reefs. The delivery components facilitate application of the active sunscreen component to the wearer's skin such that the active sunscreen component is distributed across a protected area of the wearer's skin in an effective coverage amount. The sunscreen assists in coral reef recovery, as well as improving other ocean environments, and thereby promotes ocean health.
Ranitidine tablets USP are indicated in:

  1. Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. 
  2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 
  3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 
  4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 
  5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 
  6. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg twice daily. 
  7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. 
  8. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. 



Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.
Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo. Preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively. We used 1.0 ml of 40 mg/ml nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively in 10 patients. Reduction of vestibular function was measured by the head impulse test and the caloric test. Reduction of vestibular function was found in all gentamicin patient groups. After gentamicin vestibular ablation, patients underwent home vestibular exercising for two months. The control group consisted of 10 patients who underwent only home vestibular training two months preoperatively. Postoperative rate of recovery and vertigo in both groups were evaluated with the Glasgow Benefit Inventory (GBI), the Glasgow Health Status Inventory (GHSI) and the Dizziness Handicap Inventory questionnaires, as well as survey of visual symptoms by specific questionnaire developed by us.
Subjects will be weighed in the early morning, as standard of care dictates. They will also be weighed after evening medications are given, around 9pm. The evening weight is not standard, therefore considered the study intervention.
PURPOSE:To obtain the titled irritant by bonding at least one kind of pyrazolo(3,4-d)pyrimidine or its derivative to the surface of an insoluble carrier. CONSTITUTION:The objective irritant for inducing an antineoplastic immunocyte having remarkably improved practicability, operability and safety can be produced by bonding at least one kind of pyrazolo(3,4-d)pyrimidine or its derivative [e.g. pyrazolo(3,4-d)pyrimidine, etc.] to the surface of an insoluble carrier (e.g. a hydrophilic carrier or hydrophobic carrier having the form of granule, fiber, hollow fiber, membrane, etc.) by covalent bond, ionic bond, physical adsorption, etc. The surface of the insoluble carrier has preferably a porous structure having an average pore diameter of preferably 50-3,000Angstrom . USE:It induces strong cancer-breaking cell and antineoplastic helper-T cell, and is useful not only for the remedy of cancer such as gastric cancer, pulmonary cancer, mammary cancer, hepatic cancer, etc., but also for the test of lympho cyte function of cancerous patient and the experiment of animals such as mouse.
Although activation of astrocytes is critical in developing neuropathic pain (NP) following nerve injury, the underlying mechanisms of NP and therapeutic management for NP are still vague. Importantly, the decreases in the levels of astrocytic glutamate transporter-1 (GLT-1) in the spinal dorsal horn result in enhanced excitatory transmission and cause persistent pain. P2Y1 purinergic receptor (P2Y1R) has been shown to enhance many inflammatory processes. The up-regulated expression of astrocytic P2Y1R is crucial to participate in pain transduction under conditions of nerve injury and peripheral inflammation considering that P2Y1R is potentially involved in glutamate release and synaptic transmission. This study indicates that the expression of P2Y1R in the spinal cord was increased accompanied by the activation of A1 phenotype astrocytes in the rat model of spinal nerve ligation (SNL). Astrocyte-specific knockdown of P2Y1R alleviated SNL-induced nociceptive responses and mitigated A1 reactive astrocytes, which subsequently increased GLT-1 expression. Conversely, in naïve rats, P2Y1R over-expression induced a canonical NP-like phenotype and spontaneous hypernociceptive responses and increased the concentration of glutamate in the spinal dorsal horn. Besides, our in vitro data showed that the proinflammatory cytokine tumour necrosis factor-alpha contributes to A1/A2 astrocyte reactivity and Ca2+-dependent release of glutamate. Conclusively, our results provide novel insights that as a significant regulator of astrocytic A1/A2 polarization and neuroinflammation, P2Y1R may represent a potential target for the treatment of SNL-induced NP.
Locoregionally advanced squamous cell carcinoma of the head and neck(LA-SCCHN) poses one of the most complex management challenges. This stage of disease is still potentially curable, but requires combined-modality therapy. Recent studies have showed that induction chemotherapy（neoadjuvant）reduced the 3-year distant relapse rate. Concurrent chemoradiotherapy(CCRT), on the other hand, has demonstrated a significant and consistent benefit in local control rates, but its impact on distant failure is inconsistent. Nimotuzumab is a novel EGFR-targeting monoclonal antibody that has the potential.to be used as a single agent or as a radio- and chemotherapy sensitizer for the treatment of SCCHN. Thus, investigators conducted a randomized, multicenter phaseⅡ study to compare the efficiency and safety of adding nimotuzumab to neoadjuvant and CCRT with neoadjuvant and CCRT in the treatment of patients with locoregionally advanced squamous cell carcinoma of the oropharynx and hypopharynx.
Participants will receive the sleep hygiene education component of CBT-I through Hvil®. Treatment will take 6-9 weeks.
PURPOSE: Provided is processes for preparing ecteinascidin compounds and related structure for instance, saframycines. A right amount of ecteinascidins can be used as a marine-derived anti tumor agent in vivo. CONSTITUTION: Provided are a synthetic process for the formation of ecteinascidin compounds and related structures, such as the saframycines. In one particularly preferred embodiment, a synthetic route for the formation of ecteinascidin 743 of formula(1), an exceedingly potent and rare marine-derived anti tumor agent which is slated for clinical trials are provided. The process of this invention is enantio- and stereo controlled, convergent and short. Also provided are novel process intermediates, useful not only in the total synthesis of ecteinascidin 743, but also other known ecteinascidin compounds, including derivatives and analogs thereof.
The invention provides a gastrodin controlled release preparation. The gastrodin controlled release preparation comprises a quick release part with high bioavailability and a controlled release part, wherein the gastrodin (gastrodin I) of the quick release part accounts for 30%-60% of the total weight of the gastrodin in the controlled release preparation, and the gastrodin (gastrodin II) of the controlled release part accounts for 40%-70% of the total weight of the gastrodin in the controlled release preparation. Single dose of the gastrodin controlled release preparation comprises 100-800mg of gastrodin, preferably, 300-600mg. In initial releasing stage, the gastrodin controlled release preparation is released through special quick release technology, thus accelerating the onset time, improving the bioavailability, and achieving the purpose of rapidly working; in middle and last releasing phases, the gastrodin controlled release preparation is released by controlled release technology, thus maintaining stable drug release amount, keeping stable blood concentration, improving the treatment effect of the drug, and lowering the toxic and side effects. The preparation is not affected to be released and absorbed in body by pH value and food in the body, guarantees to have slightly different treatment effect in different individuals under different conditions, and has important clinical application value. The invention provides a preparation method for the gastrodin controlled release preparation, and is applicable to industrial application.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use CiprofloxacinTabletsfor a condition for which it is not prescribed. Do not give CiprofloxacinTabletsto other people, even if they have the same symptoms that you have. It may harm them. 

This Medication Guide summarizes the most important information about CiprofloxacinTablets. If you would like more information about CiprofloxacinTablets, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about CiprofloxacinTablets that is written for healthcare professionals. For more information call 1-877-233-2001.
A method of crystallization is provided. The method includes providing a solution comprising a solute dissolved in a first solvent. The method includes providing a dispersion comprising a plurality of nanoparticles in a second solvent. The first solvent and the second solvent are mutually miscible. The method includes combining the solution and the dispersion to form a mixture. The nanoparticles remain dispersed in the mixture and the solute remains dissolved in the mixture at or below a saturation concentration. The method includes cooling the mixture such that the solute exceeds the saturation concentration forming crystals in the presence of the dispersed nanoparticles. The method includes separating the crystals from the mixture, wherein the nanoparticles remain dispersed in the mixture.
Rationale: Respiratory syncytial virus (RSV) is a common global respiratory virus that is increasingly recognized as a major pathogen in frail older adults and as a cause of chronic obstructive pulmonary disease (COPD) exacerbations. There is no single test for RSV in adults that has acceptable diagnostic accuracy. Trials of RSV vaccines have recently shown excellent safety and efficacy against RSV in older adults; defining the frequency of RSV-related community infections and COPD exacerbations is important for vaccine deployment decisions. Objectives: This prospective study aimed to establish the frequency of outpatient-managed RSV-related exacerbations of COPD in two well-characterized patient cohorts using a combination of diagnostic methods. Methods: Participants were recruited at specialist clinics in London, United Kingdom, and Groningen, the Netherlands, beginning in 2017 and observed for three consecutive RSV seasons, during exacerbations, and at least twice yearly. RSV infections were detected by RT-PCR and serologic testing. Measurements and Main Results: A total of 377 patients with COPD attended 1,999 clinic visits and reported 310 exacerbations. There were 27 RSV-related exacerbations (8.7% of the total); of these, seven were detected only by PCR, 16 only by serology, and four by both methods. Increases in RSV-specific Nucleoprotein antibody were as sensitive as those in the antibody to Pre-Fusion or Post-Fusion for serodiagnosis of RSV-related exacerbations. Conclusions: RSV is associated with 8.7% of outpatient-managed COPD exacerbations in this study. Antibodies to RSV Nucleoprotein may have diagnostic value and are potentially important in a vaccinated population. The introduction of vaccines that prevent RSV is expected to benefit patients with COPD.
Group 3 will receive a recruitment letter shipped via USPS priority mail. The letter states the participant will receive a $25 check upon enrollment into the study.
BACKGROUND: Complex regional pain syndrome (CRPS) develops after injury and is characterized by disproportionate pain, oedema, and functional loss. CRPS has clinical signs of neuropathy as well as neurogenic inflammation. Here, we asked whether skin biopsies could be used to differentiate the contribution of these two systems to ultimately guide therapy. To this end, the cutaneous sensory system including nerve fibres and the recently described nociceptive Schwann cells as well as the cutaneous immune system were analysed.
METHODS: We systematically deep-phenotyped CRPS patients and immunolabelled glabrous skin biopsies from the affected ipsilateral and non-affected contralateral finger of 19 acute (< 12 months) and 6 chronic (> 12 months after trauma) CRPS patients as well as 25 sex- and age-matched healthy controls (HC). Murine foot pads harvested one week after sham or chronic constriction injury were immunolabelled to assess intraepidermal Schwann cells.
RESULTS: Intraepidermal Schwann cells were detected in human skin of the finger-but their density was much lower compared to mice. Acute and chronic CRPS patients suffered from moderate to severe CRPS symptoms and corresponding pain. Most patients had CRPS type I in the warm category. Their cutaneous neuroglial complex was completely unaffected despite sensory plus signs, e.g. allodynia and hyperalgesia. Cutaneous innate sentinel immune cells, e.g. mast cells and Langerhans cells, infiltrated or proliferated ipsilaterally independently of each other-but only in acute CRPS. No additional adaptive immune cells, e.g. T cells and plasma cells, infiltrated the skin.
CONCLUSIONS: Diagnostic skin punch biopsies could be used to diagnose individual pathophysiology in a very heterogenous disease like acute CRPS to guide tailored treatment in the future. Since numbers of inflammatory cells and pain did not necessarily correlate, more in-depth analysis of individual patients is necessary.
INTRODUCTION: Bone marrow embolization may complicate orthopedic surgery, potentially causing fat embolism syndrome. The inflammatory potential of bone marrow emboli is unclear. We aimed to investigate the inflammatory response to femoral intramedullary nailing, specifically the systemic inflammatory effects in plasma, and local tissue responses. Additionally, the plasma response was compared to that following intravenous injection of autologous bone marrow.
METHODS: Twelve pigs underwent femoral nailing (previously shown to have fat emboli in lung and heart), four received intravenous bone marrow, and four served as sham controls. Blood samples were collected hourly and tissue samples postmortem. Additionally, we incubated bone marrow and blood, separately and in combination, from six pigs in vitro. Complement activation was detected by C3a and the terminal C5b-9 complement complex (TCC), and the cytokines TNF, IL-1β, IL-6 and IL-10 as well as the thrombin-antithrombin complexes (TAT) were all measured using enzyme-immunoassays.
RESULTS: After nailing, plasma IL-6 rose 21-fold, compared to a 4-fold rise in sham (p=0.0004). No plasma differences in the rest of the inflammatory markers were noted across groups. However, nailing yielded 2-3-times higher C3a, TCC, TNF, IL-1β and IL-10 in lung tissue compared to sham (p<0.0001-0.03). Similarly, heart tissue exhibited 2-times higher TCC and IL-1β compared to sham (p<0.0001-0.03). Intravenous bone marrow yielded 8-times higher TAT than sham at 30 minutes (p<0.0001). In vitro, incubation of bone marrow for four hours resulted in 95-times higher IL-6 compared to whole blood (p=0.03).
DISCUSSION: A selective increase in plasma IL-6 was observed following femoral nailing, whereas lung and heart tissues revealed a broad local inflammatory response not reflected systemically. In vitro experiments may imply bone marrow to be the primary IL-6 source.
Background: Spinal Cord Injury (SCI) and similar pathologies not only negatively affect a person's ability to walk but also have adverse effects on their participation in social, vocational, and recreational activities. The correction of walking impairments resulting from SCI is one of the most important goals of rehabilitation, as it is essential for a person's social and vocational integration. When considering balance function, the use of challenging balance and walking exercises at an adequate level is necessary to trigger motor learning. Ensuring the patient's safety is the primary priority when using advanced balance and walking exercises based on the patient's current condition. In this study, Andago V2.0 (Hocoma AG, Volketswil, Switzerland) has been preferred for ensuring safety by adapting to patient movements. The main objective of the study was to assess the impact of Andago on balance in patients with motor incomplete SCI. The secondary aim was to evaluate its influence on quality of life and independence. Methods: The study included five participants who were over 18 years of age and had experienced a spinal injury within the past year. These participants were classified as AIS D (American Spinal Injury Association Impairment Scale). Patients underwent eight-week treatment, with walking and balance exercises on Andago performed three days a week. In addition, conventional in-bed exercises, including stretching, strengthening, and mobility exercises, were administered for 40 minutes, two days a week. Modified Borg Scale (MBS), Ten-Meter Walking Test (10MWT), Timed Up and Go Test (TUG), Walking Index in Spinal Cord Injury II (WISCI II), Berg Balance Scale (BBS), Visual Analogue Scale (VAS) for fear of falling, Spinal Cord Independence Measure (SCIM III), World Health Organization Quality of Life Scale-Short Form (WHOQOL - BREF) were used for evaluation.